Orexo is product-focused drug delivery company that develops proprietary pharmaceuticals to address areas of unmet therapeutic need. The company’s development activities are commercially driven and is focused on tablet-based fast-dissolving or sublingual formulations for the treatment of acute conditions or
symptoms such as breakthrough pain and sleeping disorders, where a fast and reproducible onset of action is desirable. The products under development are Rapinyl®, Sublinox(TM), OX 17, OX 19 and OX 40.